Summary We examined the ability of dipyridamole (DPM) to act synergistically with vinblastine (VBL) in HT1080 fibrosarcoma cells and a drug-resistant variant, HT1080/DR4, which lacks mdrl expression, in order to determine whether DPM requires P-glycoprotein to modulate drug sensitivity. Median effect analysis of clonogenic assay was used to produce the combination index (CI.,O values <1 indicate synergy). DPM was mildly synergistic with VBL producing a CI50 of 0.83±0.13 for HT1080 cells and 0.80±0.16 for HT1080/DR4 cells. HT1080 and HT1080/DR4 cells accumulated 6.7 ±0.7 and 5.6± 0.9 pmol 3H-VBL mg cells-' at steady state (C,,) and 20 fM DPM elevated the C,, by 1.8 and 2.9-fold, respectively. In comparison, the C150 was 1.1 ±0.2 in parental KB-3-1 cells and 0.1 ±0.1 in mdrl-expressing KB-GRCI cells. The KB-3-1 and KB-GRCI cells had a C., of 3.8 ± 0.8 and 0.7± 0.2 pmol 3H-VBL mg cells-', respectively, and DPM elevated the C,, by 9.2-fold in KB-GRCI cells. These studies demonstrate that DPM can produce synergy independently of mdrl expression but that much greater levels of synergy are achievable in mdrl-expressing tumour cells.
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The emergence of multidrug resistance remains a major obstacle to the effective chemotherapy of tumours. Multidrug resistance has frequently been related to the over-expression of a 170-180 Kd molecular weight membrane-associated surface P-glycoprotein that is believed to function as an efflux pump for xenobiotics leading to reduced drug accumulation (Endicott & Ling, 1989; Juranka et al., 1989) . Multidrug resistance has also been demonstrated in various tumour cells in which there is no detectable presence of P-glycoprotein or over-expression of the mdrl gene which codes for this glycoprotein (Marsh & Center, 1987; Danks et al., 1987; Harker et al., 1989; Mirski et al., 1987; Slovak et al., 1988; Coley et al., 1991) . Recently, it has been reported that non-P-glycoprotein-mediated drug resistance preceded the development of P-glycoprotein-mediated resistance in human lung cancer cells repeatedly exposed to DOX3 (Baas et al., 1990) , indicating the presence of more than one mechanism for this phenotype.
Many agents enhance the sensitivity of multidrug resistant cells to chemotherapy but the nature of this interaction (synergy, additivity, antagonism) has not been formally determined in most cases (Asoh et al., 1989; Ramu & Ramu, 1989; Harker et al., 1986; Slater et al., 1986; Tsuruo et al., 1981) . The concept of overcoming drug resistance is based on there being a synergistic interaction between the modulator and the cytotoxic agent. Most modulators produce some degree of cell kill themselves, complicating the analysis of the interation and therefore requiring the use of isobologram or median effect analysis to determine the nature of the interaction (Chou & Talalay, 1984; Chou & Chou, 1986) .
DPM is a potent inhibitor of nucleoside transport (Plagemann et al., 1988) , phosphodiesterase activity (Harker et 1983), lipid peroxidation (Luliano et al., 1989) , and can enhance cellular sensitivity to a variety of anticancer agents (Howell et al., 1987; Howell et al., 1989a,b) . DPM has a long history of safe use in humans for the assessment and treatment of cardiovascular conditions (Fitzgerald, 1987) . We have previously conducted extensive studies examining the ability of the modulator DPM to enhance the sensitivity of VP-16, DOX, colchicine and VBL in a variety of drugsensitive and drug-resistant cell lines. There was a good correlation between the extent of synergy and the DPMinduced increase in Cs, cellular drug content (r=0.94) in human ovarian carcinoma cells (line 2008) that are relatively sensitive to all three agents (Howell et al., 1989a,b) . In contrast, DPM did not produce synergy with any cytotoxic agent in drug-sensitive human KB-3-1 carcinoma cells but did produce synergy in the drug-resistant variants which were derived from the KB-3-1 cell line (Shalinsky et al., 1990a) . The KB-GRC1 variant cell line was studied because it was produced by transfection of the mdrl gene in KB-3-1 cells and theorectically differed from the KB-3-1 cells only by the presence of a single protein, P-glycoprotein (Choi et al., 1988) , providing a useful model to study the effect of Pglycoprotein on DPM's ability to modulate drug sensitivity. In KB-GRC1 cells expressing mdrl, high levels of synergy were observed, and it was greatest for the cytotoxic agent for which expression of mdrl produced the greatest fold-resistance and enhancement of C,, (Shalinsky et al., 1990a) . How- ever, despite the fact that DPM binds to P-glycoprotein as evidenced by its ability to block 3H-azidopine labelling (Asoh et al., 1989) , there was no relationship between the extent of synergy with cytotoxic drugs and the DPM-induced increase in cellular drug content across drug-sensitive and drugresistant KB variants (Shalinsky et al., 1990a) , indicating that DPM must have other effects as well with regard to modulating drug sensitivity. These effects do not appear to be related to the ability of DPM to inhibit cAMP phosphodiesterase activity (Howell et al., 1989a) or nucleoside transport (Ramu & Ramu, 1989) which are prominent activities of DPM. Ramu and Ramu (1989) have reported that DPM selectivity increased the sensitivity of drug-resistant P388 cells to DOX but did not alter DOX sensitivity in the parental P388 cells. The effect of DPM on non-P-glycoprotein-mediated multidrug resistance is unknown.
In this study, we have employed human fibrosarcoma HT1080 cells (Rasheed et al., 1974 ) and a drug resistant variant, HT1080/DR4, which was derived from HT1080 cells following stepwise exposure to DOX and which are 222-fold resistant to this anticancer agent. The HT1080/DR4 cells represent a novel class of non-P-glycoprotein-mediated multidrug resistant cells that exhibit a stable multidrug resistant phenotype, but do not overexpress the mdrl gene as their primary mechanism of resistance (Slovak et al., 1988; Slovak et al., 1991 (Slovak et al., 1988) in the presence of 0.8 mM DOX. The KB-3-1 and KB-GRC1 cells were cultured as previously described (Shalinsky et al., 1990a Median effect analysis Median effect analysis permits a formal assessment of the nature of the interaction between drugs and yields the Cl, a measure of the extent of synergy at various levels of cell kill (Chou & Talalay, 1984) . In these studies, the CI at all levels of cell kill was determined but the CI50 was used as the most reliable measure of the drug interaction. C150 values less than 1 indicate synergy; a value of 1 indicates additivity, and values of greater than 1 indicates antagonism. In clonogenic assays employing the median effect design, dose response curves were determined for modulator and cytotoxic agent alone, and for the combination of both agents at a fixed ratio equivalent to the ratio of the ICss. Actual concentrations used in colony forming assays ranged from 1/100 of the ICm up to the actual value of the ICm for each drug as previously described (Shalinsky et al., 1990a) . The percent survival was converted to percent kill for calculation of the CI50 by computer analysis of the dose response curves (Chou & Chou, 1986 ).
Modulation of cellular pharmacology Cells were trypsinised, suspended in culture medium and plated at a density of 4 x 10' cells per 60 mm dish in 5 ml of medium. The cells were allowed to grow exponentially for 48-72 h, then the medium in each dish was removed and replaced with 2 ml of fresh medium containing 6 nM 3H-VBL (6.67 mCi jimol' ) in the absence or presence of the indicated concentration of DPM as previously described (Howell et al., 1989a,b; Shalinsky et al., 1990a sing KB-GRCl variant are included. Both multidrug resistant lines were resistant to VBL, but the HT1080/DR4 cells were only slightly resistant whereas the KB-GRC1 cell lines were highly resistant. The low level of resistance to VBL in the HT1080/DR4 cells was similar to the 2.2-fold resistance that has been reported previously (Slovak et al., 1988) .
We employed the technique of median effect analysis to determine the nature of the drug interaction between DPM and VBL in each of the cell lines. This technique produces the CI which is a measure of the nature and extent of the interaction. We utilised the CIm for analyses. CI50 values less than 1 represent synergy, a value equal to 1, additivity, and a value greater than 1, antagonism. Figure 1 compares the median effect plots for experiments employing HT1080 and HT1080/DR4 cell lines (panel a) and KB-3-1 and KB-GRC1 cell lines (panel b). The regression coefficients were > 0.9 for each drug alone and in combination with DPM, indicating that the drugs followed basic mass action principles. A similar level of synergy was observed in the HT1080 and HT1080/DR4 cell lines. The CI50 values obtained with VBL in combination with DPM was 0.83 ± 0.13 for HT1080 cells (n = 3) and 0.80 ± 0.16 for HT1080/DR4 cells (n = 4). In contrast, an additive interaction was observed with these agents in KB-3-1 cells (CI50 of 1.1 ± 0.2, n = 5) but there was a highly synergistic interaction with the KB-GRCl cells (CI50 of 0.1±0.1, n=5).
The C., of VBL was measured in the cell lines in the presence and absence of DPM in order to determine whether the synergy was related to a change in the intracellular drug content. Figure 2a shows the accumulation of VBL in the HT1080 and HT1080/DR4 cell lines and Figure 2b shows the accumulation in the KB-3-1 and KB-GRC1 cell lines. Under (Slovak et al., 1991 and KB-GRCI (0) cells over the entire range of cell kill. A combination index of (----) indicates additivity; < shows synergy and > shows antagonism. In clonogenic assays employing the median effect design, dose-response curves were generated for DPM and VBL alone and in combination as described in Materials and methods. Each point is plotted as the mean combination index from 3-6 experiments, s.d<20%. control conditions, the HT1080 cells had a C.5 of 6.7 ± 0.7 pmol VBL mg cellular protein-' compared to a C. of 5.6 ± 0.9 pmol VBL mg cellular protein-' in the HT1080/ DR4 cells. In contrast, whereas the C. was 3.8 ± 0.8 in the KB-3-1 cells, it was only 0.7 ± 0.2 pmol VBL mg protein-1 in the KB-GRC1 cells. The much lower C. in the KB-GRCl vs the KB-3-1 cells is consistent with the presence of a functioning P-glycoprotein pump in these cells, whereas the small difference in C. in the HT1080/DR4 cells relative to the parental HT1080 cells reflected the lack of P-glycoprotein in these resistant variants. As shown, the C". was achieved in each cell line after 1 h incubation. Therefore, further incubations with VBL were performed using this duration of exposure. Figure 3a shows the ability of DPM to enhance the C5. of VBL in HT1080 and HT1080/DR4 cells and Figure 3b illustrates this for the KB-3-1 and KB-GRCI cells. DPM produced maximum increases in the C., of VBL of 1.8 and 2.9-fold in the HT1080 and HT1080/DR4 cells, respectively. In HT1080 and HT1080/DR4 cells, the dose response curve reached a plateau by 10 and 20 1M, respectively. DPM produced increases in the C., of VBL in KB-3-1 and KB-GRCI cells of 1.7 and 9.2-fold, respectively. In KB-3-1 and KB-GRC1 cells, the dose response curve reached a plateau by 1O JM DPM. Hence, DPM had similar effects in approximately doubling the C. of VBL in each of the drug-sensitive cell lines but DPM produced a much higher relative increase in C,, in the KB-GRCI than the HT1080/DR4 cell line.
Discussion
In previous studies (Shalinsky et al., 1990a) , we found a high degree of synergistic interaction between DPM and VBL in (0) (Beck et al., 1983; Sirotnak et al., 1986; Slovak et al., 1988 (Howell et al., 1989a,b (Shalinsky et al., 1990a) . VPL also elevates the C,, of VBL which is consistent with the ability of VPL to bind to P-glycoprotein as demonstrated by Cornwell et al. (1987) and Safa (1988) . VPL is about one fifth to one half as potent as DPM in KB-GRC1 (Shalinsky et al., 1990b) and 2008 cells (Howell et al., 1989b) , respectively, suggesting that VPL, as well as DPM, has a P-glycoprotein-dependent and -independent mechanism for elevating C. and producing synergy in tumour cells. The identification of P-glycoprotein-independent mechanism(s) may permit broader use a modulators for enhancement of cytotoxicity against drug-sensitive as well as drug-resistant neoplasms, but this potential can not be realised until the underlying mechanisms in drug-sensitive tumour cells are identified.
This study demonstrates that a very high level of synergy is achievable with VBL in combination with DPM in multidrug resistant tumour cells that overexpress mdrl. VPL also produces an equally high level of synergy with VBL in KB-GRC1 cells (Shalinsky et al., 1990a 
